MedTrace Logo

A Study of Ramelteon in Chinese Patients With Chronic Insomnia

NCT06512363 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2024-07-22

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of Ramelteon in chinese patients with chronic insomnia.

Efficacy will be evaluated on objective and subjective sleep parameters.

Conditions

  • Chronic Insomnia

Interventions

DRUG

Ramelteon

Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.

DRUG

Ramelteon placebo

Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.

Sponsors & Collaborators

  • Nanjing Chia-tai Tianqing Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-31
Primary Completion
2026-12-31
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06512363 on ClinicalTrials.gov